Equities Analysts Set Expectations for JAZZ Q4 Earnings

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – Research analysts at Zacks Research lowered their Q4 2025 earnings estimates for shares of Jazz Pharmaceuticals in a report released on Monday, February 2nd. Zacks Research analyst Team now forecasts that the specialty pharmaceutical company will post earnings per share of $5.15 for the quarter, down from their prior estimate of $5.16. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $16.96 per share. Zacks Research also issued estimates for Jazz Pharmaceuticals’ Q2 2026 earnings at $4.88 EPS, Q3 2026 earnings at $5.25 EPS, Q4 2026 earnings at $5.00 EPS, Q2 2027 earnings at $5.04 EPS, Q3 2027 earnings at $5.70 EPS, Q4 2027 earnings at $5.50 EPS and FY2027 earnings at $20.06 EPS.

Several other research firms have also commented on JAZZ. Bank of America boosted their price target on Jazz Pharmaceuticals from $230.00 to $247.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. JPMorgan Chase & Co. dropped their price objective on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a research note on Monday, October 27th. Needham & Company LLC upped their target price on shares of Jazz Pharmaceuticals from $210.00 to $235.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Wells Fargo & Company lifted their price target on shares of Jazz Pharmaceuticals from $170.00 to $235.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 18th. Finally, Robert W. Baird boosted their price objective on shares of Jazz Pharmaceuticals from $160.00 to $209.00 and gave the stock an “outperform” rating in a report on Tuesday, November 18th. Fourteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $205.67.

Jazz Pharmaceuticals Trading Down 0.7%

Shares of JAZZ opened at $165.72 on Wednesday. Jazz Pharmaceuticals has a 12 month low of $95.49 and a 12 month high of $182.99. The stock’s 50-day moving average is $168.36 and its two-hundred day moving average is $144.82. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.65 and a quick ratio of 1.44. The stock has a market cap of $10.07 billion, a PE ratio of -27.30, a P/E/G ratio of 0.90 and a beta of 0.26.

Institutional Trading of Jazz Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of JAZZ. Vestal Point Capital LP acquired a new position in shares of Jazz Pharmaceuticals in the 2nd quarter valued at about $127,344,000. Goldentree Asset Management LP acquired a new position in Jazz Pharmaceuticals in the third quarter valued at approximately $149,597,000. Schonfeld Strategic Advisors LLC grew its holdings in shares of Jazz Pharmaceuticals by 592.1% during the third quarter. Schonfeld Strategic Advisors LLC now owns 436,443 shares of the specialty pharmaceutical company’s stock valued at $57,523,000 after purchasing an additional 373,383 shares during the last quarter. AQR Capital Management LLC raised its position in shares of Jazz Pharmaceuticals by 62.1% during the 2nd quarter. AQR Capital Management LLC now owns 794,770 shares of the specialty pharmaceutical company’s stock worth $84,341,000 after purchasing an additional 304,463 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Jazz Pharmaceuticals by 11.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock worth $373,855,000 after purchasing an additional 298,815 shares during the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, EVP Robert Iannone sold 7,159 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $168.26, for a total transaction of $1,204,573.34. Following the sale, the executive vice president directly owned 72,628 shares of the company’s stock, valued at approximately $12,220,387.28. This represents a 8.97% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Heather Ann Mcsharry sold 3,415 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $177.78, for a total transaction of $607,118.70. Following the completion of the transaction, the director directly owned 20,449 shares of the company’s stock, valued at approximately $3,635,423.22. This represents a 14.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 123,791 shares of company stock valued at $21,991,850. Corporate insiders own 4.30% of the company’s stock.

Trending Headlines about Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Zacks raised its FY2027 EPS estimate to $20.06 (from $19.95), signaling stronger long‑term earnings expectations. MarketBeat Report
• Positive Sentiment: Zacks increased Q4 2027 EPS to $5.50 (from $5.45), a small lift that supports the FY2027 upgrade. MarketBeat Report
• Positive Sentiment: Zacks nudged up Q3 2027 to $5.70 (from $5.66) and Q2 2027 to $5.04 (from $5.03), indicating incremental confidence in mid‑2027 results. MarketBeat Report
• Positive Sentiment: Zacks raised Q4 2026 to $5.00 (from $4.96) and Q1 2027 to $3.82 (from $3.80), small upward tweaks to near‑term quarters. MarketBeat Report
• Negative Sentiment: Zacks trimmed Q3 2026 slightly to $5.25 (from $5.26) and cut Q2 2026 to $4.88 (from $4.90), modest downgrades to some nearer‑term quarters. MarketBeat Report
• Negative Sentiment: Zacks also nudged Q4 2025 down to $5.15 (from $5.16); these cuts are very small but contribute to the mixed picture. MarketBeat Report

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.